Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

NCT04126993 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Camrelizumab,
DRUG: Apatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital